Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)

13 de julho de 2026 atualizado por: Gao-Jun Teng, Zhejiang Cancer Hospital

Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial

This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.

Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.

The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

140

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Gaojun Teng, MD
  • Número de telefone: +86 13805171500
  • E-mail: gjteng@seu.edu.cn

Estude backup de contato

Locais de estudo

    • Guangdong
      • Guangzhou, Guangdong, China, 510060
      • Guangzhou, Guangdong, China, 510317
        • Guangdong Second People's Hospital
        • Contato:
      • Guangzhou, Guangdong, China, 510168
        • Jinshazhou Hospital of Guangzhou University of Chinese Medicine
        • Contato:
      • Guangzhou, Guangdong, China, 511400
        • The Affiliated Panyu Central Hospital of Guangzhou Medical University
        • Contato:
      • Guangzhou, Guangdong, China, 524003
        • The Second Affiliated Hospital of Guangdong Medical University
        • Contato:
      • Jiangmen, Guangdong, China, 529030
        • Jiangmen Central Hospital
        • Contato:
          • Yuchuang Liang
          • Número de telefone: +86 13322888181
          • E-mail: jmlyc@21cn.com
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Wuhan Union Hospital of China
        • Contato:
    • Hunan
      • Changsha, Hunan, China, 410013
        • The Third XIANGYA Hospital of Central South University
        • Contato:
      • Changsha, Hunan, China, 410011
        • The Second Xiangya Hospital of Central South University
        • Contato:
    • Jiangxi
      • Ganzhou, Jiangxi, China, 341000
        • Ganzhou Hospital-Nanfang Hospital, Southern Medical University
        • Contato:
      • Nanchang, Jiangxi, China, 330209
        • The First Affiliated Hospital of Nanchang University
        • Contato:
    • Shandong
      • Qingdao, Shandong, China, 266000
        • The Affiliated Hospital of Qingdao University
        • Contato:
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
        • Contato:
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310022
        • Zhejiang Cancer Hospital
        • Contato:
        • Contato:
        • Subinvestigador:
          • Jiaping Zheng
      • Jinhua, Zhejiang, China, 321000
        • Jinhua Municipal Central Hospital
        • Contato:
      • Lishui, Zhejiang, China, 323020
      • Ningbo, Zhejiang, China, 315010
        • Ningbo No.2 Hospital
        • Contato:
      • Ningbo, Zhejiang, China, 315048
        • Ningbo Medical Center Lihuili Hospital
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  1. Age ≥18 years.
  2. Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
  3. No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
  4. At least one measurable intrahepatic lesion according to RECIST v1.1.
  5. ECOG performance status of 0 or 1.
  6. Child-Pugh class A liver function.
  7. Life expectancy ≥3 months.
  8. Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:

    • Absolute neutrophil count ≥1.5 × 10⁹/L;
    • Platelet count ≥75 × 10⁹/L;
    • Hemoglobin ≥90 g/L;
    • Serum albumin ≥30 g/L;
    • Total bilirubin ≤1.5 × upper limit of normal;
    • AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
    • TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
    • Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.

Exclusion Criteria:

  1. Diffuse infiltrative liver lesions.
  2. Contraindications to TACE.
  3. Allergy to intravenous contrast agent.
  4. pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
  5. Patients with HIV or syphilis infection.
  6. Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
  7. History of allogeneic organ transplantation.
  8. Severe dysfunction of the heart, kidney, or other organs.
  9. Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
  10. Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg. TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment. Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion. Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed. TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
Comparador Ativo: Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles. After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks. Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Overall Survival
Prazo: From randomization to death from any cause, assessed up to approximately 48 months
Overall survival is defined as the time from enrollment/randomization to death from any cause. Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
From randomization to death from any cause, assessed up to approximately 48 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Progression-Free Survival
Prazo: From randomization to disease progression or death, assessed up to approximately 48 months
Defined as the time from randomization to disease progression or death from any cause. Participants without progression or death will be censored at the last date known to be progression-free.
From randomization to disease progression or death, assessed up to approximately 48 months
Time to Progression
Prazo: From randomization to disease progression, assessed up to approximately 48 months
Defined as the time from randomization to disease progression. Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
From randomization to disease progression, assessed up to approximately 48 months
Objective Response Rate
Prazo: Assessed every 6 weeks ±7 days, up to approximately 48 months
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
Assessed every 6 weeks ±7 days, up to approximately 48 months
Disease Control Rate
Prazo: Assessed every 6 weeks ±7 days, up to approximately 48 months
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
Assessed every 6 weeks ±7 days, up to approximately 48 months
Incidence of Grade ≥3 Adverse Events
Prazo: From first dose of study treatment through 28 days after the last dose of study treatment
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
From first dose of study treatment through 28 days after the last dose of study treatment
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Prazo: Baseline and during treatment/follow-up, assessed up to approximately 48 months
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer. Scores are linearly transformed to a 0 to 100 scale. For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning. For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
Baseline and during treatment/follow-up, assessed up to approximately 48 months
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
Prazo: Baseline and during treatment/follow-up, assessed up to approximately 48 months
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life. The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity. Higher scores in each dimension indicate more severe problems or worse health status.
Baseline and during treatment/follow-up, assessed up to approximately 48 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Gaojun Teng, MD, Zhejiang Cancer Hospital
  • Investigador principal: Min Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
  • Investigador principal: Jiansong Ji, MD, The Central Hospital of Lishui City

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de julho de 2026

Conclusão Primária (Estimado)

1 de janeiro de 2030

Conclusão do estudo (Estimado)

1 de julho de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

30 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de junho de 2026

Primeira postagem (Real)

9 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

14 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared due to privacy, ethical, and regulatory considerations.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever